Describe the problem before naming a product
Write down the symptoms or concerns that led you to consider sermorelin, when they began and how they affect daily life. Include relevant changes in sleep, work, exercise, nutrition or existing care. This gives the clinician a more useful starting point than a request to match a particular advertised protocol.
Ask what else might explain the concern and whether evaluation by your usual clinician or a specialist is appropriate. A treatment page's list of possible benefits is not a diagnostic checklist, and an age-related change does not automatically establish a need for a hormone-related prescription.
Bring a complete health and medication history
Provide current prescriptions, nonprescription medicines, supplements and other peptide or hormone products, including where they came from. Share relevant diagnoses, previous reactions, pregnancy or breastfeeding considerations and any cancer or pituitary history with the clinician. The purpose is to support a personal assessment, not to self-approve treatment by checking boxes.
AgelessRx and Strut publish screening and safety information, but their pages are not complete substitutes for medical review. Do not omit a condition because it does not appear in the marketing FAQ, and do not stop an existing medication to meet an online program's entry criteria.
Ask what is being diagnosed or treated
Clarify whether the clinician is investigating a specific deficiency, evaluating symptoms or proposing a treatment outside an approved indication. Ask what evidence supports the choice and which alternatives could address the same problem. If testing is proposed, understand what decision it will inform.
The Endocrine Society guideline for adult growth-hormone deficiency emphasizes individualized judgment and a defined diagnostic approach. It is not a blanket endorsement of hormone optimization for everyone with fatigue or advancing age. The clinical explanation should be more specific than a promise to restore youthful levels.
Agree on follow-up and communication
Ask how benefit and unwanted effects will be evaluated, when the first review occurs and who can change the prescription. Identify a clinical contact for concerns, the usual response process and what the service instructs patients to do outside its routine availability. Customer-service access and medical assessment are different functions.
If the proposed product is compounded, discuss that status explicitly. FDA does not approve compounded drugs or review them before marketing for safety, effectiveness and quality. Ask why this formulation is being considered and what information the dispensing pharmacy will supply.
Finish with a usable written plan
The consultation should leave you with the proposed medication and route, the reason for using it, any further assessment needed, the follow-up plan and the complete costs to confirm. Ask what happens if you are not eligible or if the recommendation changes after reviewing records. There may be no prescription at the end of an appropriate assessment.
Keep the medical plan separate from the promotional deadline or subscription discount. You should be able to review the price, renewal and cancellation terms without treating them as a reason to accept an uncertain recommendation. This checklist supports a conversation; it does not determine eligibility or prescribe a regimen.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.